Core Insights - uniQure N.V. has appointed Kylie O'Keefe as Chief Customer and Strategy Officer to lead the commercialization of AMT-130 for Huntington's disease, effective June 6, 2025 [1][2] - The company is preparing for a potential U.S. commercial launch of AMT-130 in 2026, leveraging O'Keefe's extensive experience in rare diseases and gene therapy [2][3] - AMT-130 is positioned as a potential first disease-modifying treatment for Huntington's disease, with a clear path towards accelerated approval in the U.S. [3] Company Overview - uniQure is a leading gene therapy company focused on developing transformative therapies for patients with severe medical needs, including Huntington's disease, ALS, and Fabry disease [4] - The company has achieved significant milestones, including the approval of its gene therapy for hemophilia B, marking a major advancement in genomic medicine [4] Leadership Background - Kylie O'Keefe has a strong background in biopharmaceuticals, having previously served as Chief Commercial Officer at PTC Therapeutics, where she managed global commercial strategy for rare neurology and metabolic products across over 50 countries [2] - O'Keefe's experience includes leading significant commercial launches and developing reimbursement strategies, which will be crucial for uniQure's commercialization efforts [2]